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Regioisomers of the functional group of the main ligand (L) on a series of [Ru(phen)2L]2+and [Ru(bpy)2L]2+
complexes, where phen is 1,10 phenanthroline and bpy is 2,2′-bipyridine, were synthesised to investigate the
interaction with deoxyribonucleic acid (DNA) as potential therapeutics. UV–Vis binding titrations, thermal
denaturation and circular dichroism were used to evaluate their interaction with DNA. The conclusions indicated
the signiﬁcance of the auxiliary ligand; especially 1,10-phenanthroline has on the binding constants (Kb). The
systematic variation of auxiliary ligand(phen or bpy), and polypyridyl ligand (4-(1H-Imidazo[4,5-f][1,10]phenanthrolin-2-yl)benzonitrile (CPIP), 2-(4-formylphenyl)imidazo[4,5-f] [1,10] phenanthroline (FPIP), 2-(4-bromophenyl)imidazo[4,5-f][1,10]phenanthroline (BPIP) and 2-(4-nitrophenyl)imidazo[4,5-f] [1,10] phenanthroline (NPIP), split in terms of functional group change were investigated for DNA interaction. The CPIP analogues
in particular were investigated for the regioisomerism (ortho, meta, para) eﬀect of the nitrile group on the ligand.
It was found that both the DNA interaction could be tailored through the systematic variation of the electronic
nature of the individual auxiliary ligand and to a lesser extent the functional group and regioisomeric change.
Preliminary cell line studies have been carried out to determine the selectivity of the complexes against cell lines
such as A375 (Skin Cancer), HeLa (Cervical Cancer), A549 (Lung Cancer), Beas2B (Lung Normal Cell) and MCF-7
(Breast Cancer). Complexes which had strong DNA interactions in the binding studies have proven to be the most
eﬃcacious against certain cell lines. Establishing well-deﬁned structure property relationships when looking at
trends in spectroscopic properties and DNA binding will aid in the intelligent design of potential therapeutic
complexes.

1. Introduction
The potential application of ruthenium (II) complexes as anticancer compounds is being widely explored [1,2]. This decade is also
witnessing the advent of ruthenium (II) polypyridyl complexes entering clinical trials [3] and with many more showing promising
biological properties [4–12]. The synthesis of a series of novel systematically varied ruthenium (II) complexes (Fig. 1), altered either by
changing (i) the auxiliary ligands (1,10 phenathroline (phen) and 2,2′bipyridine (bpy)), (ii) by the end group substituent upon the polypyridyl main ligand ((1H-Imidazo[4,5-f][1,10]phenanthrolin-2-yl)
benzonitrile (CPIP), 2-(4-formylphenyl)imidazo[4,5-f] [1,10] phenanthroline (FPIP), 2-(4-bromophenyl)imidazo[4,5-f][1,10]phenanthroline
(BPIP)
and
2-(4-nitrophenyl)imidazo[4,5-f]
[1,10]

⁎

phenanthroline (NPIP)) and (iii) by changing the position of the
functional group on the CPIP ligand (regioisomers – para, meta, ortho).
Synthetically modifying one variable upon the complex structure, allows the study of how these speciﬁc chemical functionalities inﬂuence
the deoxyribonucleic acid (DNA) intercalating aﬃnities. Table 1.0
shows a library of ligands and complexes both previously published
and novel that were employed in this study.
The novel regioisomeric ligands; p-CPIP m-CPIP and o-CPIP, where
the nitrile substituent changes position on a polypyridyl ligand structure (x = para, meta and ortho) allowed the synthesis of a further six
novel complexes of the structure; [Ru(bpy)2x-CPIP]2+ and [Ru
(phen)2x-CPIP]2+. The literature based ligands FPIP, NPIP and m-FPIP
allowed for synthesis of comparative literature based Ru(II) complexes;
[Ru(bpy)2p-FPIP]2+, [Ru(bpy)2p-NPIP]2+, [Ru(phen)2p-FPIP]2+, [Ru
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Abbreviations

Kb
binding constant
MALDI-TOF matrix-assisted laser desorption ionization time-of
ﬂight
MCF-7
breast cancer cell line
MLCT
metal to ligand charge transfer
MOPIP 2-(4-methoxyphenyl)imidazo[4,5-f] [1,10] phenanthroline
MS
mass spectroscopy
MTT
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NAMI
sodium trans-(dimethylsulfoxide)(imidazole)tetrachloro
ruthenate(III)
NMR
Nuclear Magnetic Resonance
NPIP
2-(4-nitrophenyl)imidazo[4,5-f] [1,10] phenanthroline
PBS
phosphate buﬀered saline
Phen
1,10 Phenanthroline
Pip
2-phenyl-imidazo[4,5-f]1,10-phenanthroline
ppm
parts per million
RAP
dichloro-1,2-propylenediamine tetraacetate ruthenium
(III)
RPMI
Roswell Park Memorial Institute
TD
thermal denaturation
Tm
melting temperature
UV/Vis ultraviolet/visible

A375
A549
APIP

skin cancer cell line
lung cancer cell line
2-(2-Aminophenyl)imidazo [4,5-f][1,10]phenanthroline
Beas2B Lung normal cell line
BﬁpH
2-(benzofuran-2-yl)imidazo[4,5-f] [1,10] phenanthroline
BPIP
2-(4-bromophenyl)imidazo[4,5-f] [1,10] phenanthroline
Bpy
2, 2′ bipyridine
Calc
calculated
CT-DNA calf thymus-DNA
CD
circular dichroism
CPIP
2-(4-cyanophenyl)imidazo[4,5-f] [1,10] phenanthroline
DBHIP
2-(3,5-dibromo-4-hydroxyphenyl)imidazo[4,5-f][1,10]
phenanthroline
DMSO
dimethylsulphoxide
DNA
deoxyribonucleic acid
ES-MS
electrospray ionization mass spectroscopy
FBS
foetal bovine serum
FPIP
2-(4-formylphenyl)imidazo[4,5-f] [1,10] phenanthroline
HAPIP
2-(2-Hydroxyl-5-aminophenyl)imidazo [4,5-f][1,10]-Phenanthroline
HeLa
cervical cancer cell line
HPIP
2-(4-hydroxyphenyl)imidazo[4,5-f] [1,10] phenanthroline
IC50
half the maximal inhibitory concentration

2+

2+

N

N

N
N

N

Ru
N

N
N

R3

N

H
N

N

N

Ru

R1
N
H

N

R3

N

R2

R1
R2

N

Fig. 1. Molecular structure of the ruthenium complexes where R is (CHO), (NO2), (Br) or (CN) and R1 = para, R2 = meta, R3 = ortho positions.

(phen)2p-BPIP]2+ and [Ru(phen)2pNPIP]2+ [13–17]. This study includes the synthesis of a series of ligands based on a 1,10-phenanthroline-5, 6-dione (phendione) backbone. The main strategy behind

building these conjugated heteroaromatic ligands was to increase the
binding ability of polypyridyl Ru(II) complexes with a pendant arm
containing a second binding moiety with high aﬃnity for DNA. Barton
and co-workers synthesised novel metal complexes bearing at least one
strongly intercalating ligand, i.e., metallointercalators containing an
expanded aromatic heterocyclic ligand, which can readily allow
stacking interactions within the DNA double helix [2,18].
For the ruthenium anticancer complexes molecular mechanistic
studies are only at the beginning [19]. Mechanistic studies on both
platinum and ruthenium compounds have, however, opened many new
avenues of research that may lead to the design of completely new
drugs [19].A recent perspective article by Alessio et al., categorised
metal anticancer compounds based on their mode of action, which
could be divided into ﬁve diﬀerent classes: 1. The metal has a functional role, 2. The metal has a structural role, 3. The metal is a carrier
for main ligands that are delivered in vivo. 4. The metal compound
behaves as a catalyst in vivo, 5. The metal compound is photoactive
[20]. Elucidation and optimisation of the mode of action of anticancer
agents in classes 2, 4, and 5 as deﬁned by Alessio et al. require an
intimate knowledge of both the structural and electronic properties of
the complexes. Thus to fully realise the advantages of ruthenium

Table 1
All the Ru(II) complexes synthesised within this study. Novel complexes highlighted with
asterisk*.
Complex
[Ru(bpy)2L]

2+

[Ru(phen)2L]2+

Ligand (L)

R1

R2

R3

p-FPIP
m-FPIP
p-NPIP
p-BPIP
p-CPIP*
m-CPIP*
o-CPIP*
p-FPIP
m-FPIP
p-NPIP
p-BPIP
p-CPIP*
m-CPIP*
o-CPIP*

CHO
H
NO2
Br
CN
H
H
CHO
H
NO2
Br
CN
H
H

H
CHO
H
H
H
CN
H
H
CHO
H
H
H
CN
H

H
H
H
H
H
H
CN
H
H
H
H
H
H
CN
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completed employing IR and Raman spectroscopy on each ligand to
fully characterise the molecular structure. Elemental analyses (CHN)
were carried out by the Microanalytical Department, University College
Dublin. MALDI-TOF mass spectroscopy was completed by the Mass
Spectrometry Unit in Trinity College Dublin on the novel ligands.
The following ligands were prepared to investigate the regioisomers
(ortho, meta, para) of the end group on the main ligand and to observe
its eﬀect on the DNA intercalating properties of the resulting ruthenium
complexes.

complexes as novel inorganic therapeutics, it is crucial that the photophysical processes which govern the reactivity of the complexes are
fully and comprehensively understood [20].
Many research teams have embraced the phen structure into the
synthesis of a variety of planar polypyridyl ligands [6,8,9] with different end group position in the phenyl ring, developed on from the
planar ligand for example; 2-phenyl-imidazo[4,5-f]1,10-phenanthroline
(PIP) consisting of the a basic phenyl ring [21]. Increasing the surface
area of the phen polypyridyl ligand has seen to increase the DNA
binding aﬃnity of the complex [21]. Promising activity has been observed for these phen functionalised ligand as ruthenium based complexes, Li et al. synthesised a similar series of these style ligands; pMOPIP with OMe group (2-(4-methoxyphenyl)imidazo[4,5-f] [1,10]
phenanthroline) (R1 (para) position on the phenyl ring), p-HPIP with
OH group2-(4-hydroxyphenyl)imidazo[4,5-f] [1,10] phenanthroline
and p-NPIP with NO2 group (2-(4-nitrophenyl)imidazo[4,5-f] [1,10]
phenanthroline) [10]. Antitumour activity was observed against L1210
cells, Human oral epidermoid carcinoma KB cells (HeLa cell derivative),
human promyelocytic cells, HL-60 and Bel- 7402 cancer cells by MTT
assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay). Promising intercalative DNA binding ability and cytotoxic observations for these ruthenium based polypyridyl complexes indicate
that modiﬁcation of the ligands have led to subtle changes in their
binding modes, location and aﬃnities with DNA [ 22–24].
In more recent times a trend in medicinal chemistry has been a
trend away from high-throughput approaches to drug discovery (i.e.
those where vast databases of molecules are screened against a biological target) towards structure-based drug discovery (i.e. those where
drug design is based on speciﬁc structural information about a biological target) [25]. The coordination compounds of Ru(II) were synthesised with the following nitrogen donor ligands; 2, 2′-bipyridine
(bpy) and 1,10-phenanthroline (phen). The step-by-step substitution of
the functional group on the polypyridyl ligand allows analysis with
essentially a single variable, increasing the electron aﬃnity of the
terminal group on the polypyridyl ligand. The eﬀect of the systematic
change on the complexes properties is investigated using a series of
ruthenium complexes with the end-group terminations varied from 2(4-formylphenyl)imidazo[4,5-f] [1,10] phenanthroline [p-FPIP], 2-(4cyanophenyl)imidazo[4,5-f] [1,10] phenanthroline [p-CPIP], 2-(4-bromophenyl)imidazo[4,5-f] [1,10] phenanthroline [p-BPIP], to 2-(4-nitrophenyl)imidazo[4,5-f] [1,10] phenanthroline [p-NPIP]. The regioisomeric change was investigated for the complexes of the CPIP
ligand.

2.2. Synthesis of ligands
2.2.1. Synthesis
of
4-(1H-Imidazo[4,5-f][1,10]phenanthrolin-2-yl)
benzonitrile (p-CPIP)
The ligand was synthesised in an identical manner as described for
p-FPIP by Liu et al. [15] with 4-formylbenzonitrile (314 mg, 2.5 mmol)
in place of terephthalic aldehyde. Yield: 0.5115 g (63.6%). υ (cm−1)
2226.6 s, 1611.1 m, 1553.0 m, 1480.6 m, 1397.8 m, 802.6 s and 737.9 s.
MALDI-TOF MS (m/z) [M + H]+: Actual mass: 322.1096; Calculated
mass: 322.1093. 1H NMR (400 MHz, d6-DMSO) ppm: 9.0 (dd 2H
7,8 J = 1.6, 1.6, 4, 4), 8.91(dd 2H 5,10 J = 2, 1.6, 8.4, 8), 8.35 (d,
2H,3, 11 J = 8.4), 8.03 (d, 2H 2,12 J = 8.4), 7.78 (dd 2H 6,9 J = 4.4,
4.4, 8, 8). 13C NMR (400 MHz, d6-DMSO) [ppm]: 148.6 (C23,26),
148.17(C19,30), 143.84 (C24,25), 133.97 (C20, 29), 133.04(C15,32),
129.71 (C16,31), 126.61 (C21,28), 123.41(C22,27), 118.67 (C13)
111.42 (C14).
2.2.2. Synthesis
of
3-(1H-Imidazo[4,5-f][1,10]phenanthrolin-2-yl)
benzonitrile (m-CPIP)
The ligand was synthesised as described for p-CPIP with 3-formylbenzonitrile (156 mg, 1.18 mmol) in place of 4-formylbenzonitrile.
Yield: 0.245 g (64%). υ (cm−1) 2231.4 s, 1606.2 m, 1547.2 m,
1471.2 m, 1400.3 m, 804.6 s and 736.3 s. MALDI-TOF MS (m/z)
[M + H]+: Actual mass: 322.1098; Calculated mass: 322.1093. 1H
NMR (400 MHz, d6-DMSO) ppm: 9.04 (dd 2H 7,8, J = 1.6, 1.6, 4.4,
4.4), 8.87 (dd 2H 5,10 J = 1.6, 1.6, 8, 8), 8.61 (s,1H, 11), 8.56 (d,
1H,3), 7.89 (d, 1H 1), 7.77 (m 3H 2, 6, 9).13C NMR (400 MHz, d6DMSO) [ppm]: 173.13(C18) 149.43 (C19,30), 147.54(C23,26), 143.49
(C24,25), 132.12 (C14), 130.45 (C16), 130.177 (C15), 129.56
(C21,28), 129.16 (C31), 123.17 (C22,27), 121.87(C20,29),
118.67(C13), 111.92(C32).
2.2.3. Synthesis
of
2-(1H-Imidazo[4,5-f][1,10]phenanthrolin-2-yl)
benzonitrile (o-CPIP)
The ligand was synthesised in an identical manner as described for
p-CPIP with 2-formylbenzonitrile (156 mg, 1.18 mmol) in place of 4formylbenzonitrile. Yield: 0.133 g (35%). υ (cm−1) 2229.9 s, 1600.0 m,
1569.6 m, 1481.6 m, 1399.9 m, 808.0 s and 737.4 s. MALDI-TOF MS
(m/z) [M + H]+: Actual mass: 322.1092; Calculated mass: 322.1093.
1
H NMR (400 MHz, d6-DMSO) ppm: 9.04 (dd 2H 7,8 J = 1.6, 2, 4, 4.4),
8.87 (dd 2H 5,10 J = 1.6, 2, 8, 8.4), 8.33 (d, 1H, 3, J = 7.8), 8. 01(d,
1H, 12, J = 7.8), 7.85 (d of t, 1H, 2 J = 7.8, 7.6), 7.81 (m, 2H, 6,9) 7.63
(d of t, 1H, 1 J = 7.6, 7.6). 13C NMR (400 MHz, d6-DMSO) [ppm]:
172.844(C18) 149.29 (C19,30), 147.48(C23,26), 143.52 (C24,25),
135.16 (C32), 133.71 (C20,29), 133.71 (C15), 129.73 (C21,28), 129.08
(C14), 128.75 (C16), 123.23(C22,27), 122.284 (C17),118.82(C13),
109.47(C31).

2. Experimental
2.1. Materials and methods
Reagents and solvents were used without further puriﬁcation and
purchased from Sigma Aldrich and Fisher Scientiﬁc. 1,10-phenanthroline-5,6-dione was prepared by the procedure described by Zheng et al.
[26] Synthesis of 2-(4-formylphenyl)imidazo[4,5-f] [1,10] phenanthroline (p-FPIP) (also abbreviated to fmp)was prepared following the
method reported by He et al. [ 17] Synthesis of 4-(1H-Imidazo[4,5-f]
[1,10]phenanthrolin-2-yl)benzaldehyde (m-FPIP) was synthesised in an
identical manner as described for p-FPIP and by Chao et al. [14]
Synthesis of 2-(4-nitrophenyl)imidazo[4,5-f] [1,10] phenanthroline (pNPIP) was prepared in an identical manner as described for p-FPIP and
by Liu et al. [15] Synthesis of 2-(4-bromophenyl)imidazo[4,5-f][1,10]
phenanthroline (p-BPIP) was synthesised in an identical manner as
described for p-FPIP and by Sergeeva et al. [27]
The ligands were characterised by 1H, 13C, COSY, HSQC, IR, Raman
spectroscopy and elemental analysis. The experiments were carried out
at room temperature (300 K). Absorption spectroscopy and luminescence measurements were performed on each polypyridyl ligand in
ethanol at a concentration of 0.025 mM. A full vibrational study was

2.3. Synthesis of complexes
The general synthetic methods for the dichloride ruthenium complexes are well known and gave good yields [28]. All of the literature
reference based complexes were prepared according to their literature
methods. [13–16,29] [Ru(bpy)2FPIP]2+ and [Ru(bpy)2m-FPIP]2+ was
prepared by Chao et al. [13,14], [Ru(bpy)2NPIP]2+ was prepared by
Shuo et al. [29], [Ru(phen)2p-NPIP]2+ was prepared by Liu et al. [15],
73
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[Ru(phen)2 p-BPIP]

2+

132.04, 130.42(C43, 58), 128.04 (C34, 35, 66, 67), 126.28& 126.01
(C54, 30, 39, 62, 71, 42, 59).

was prepared by Xu et al. [16]

2.3.1. Synthesis of [Ru(bpy)2p-CPIP]2+
The complex was synthesised in an identical manner as described
for [Ru(bpy)2p-FPIP]2+ by Chao et al. [13], with p-CPIP (0.080 g,
0.3 mmol) replacing p-FPIP. Yield: 0.143 g (78%). Elemental analysis
(%) Calculated for [Ru(C10H8N2)2(p-C20H11N5)][PF6]2·3(H2O): C 44.54,
H: 3.08, N: 11.69; found C 44.46, H: 3.10, N: 11.42. ES-MS of the PF6−
salt [(M+-(PF6))]: m/z 880.2 (calc 880.1) and 367.6, resolution of the
peak 367.6 shows the species is double charged and the isotope distribution corresponds to the calculated one. 1H NMR (400 MHz) in
(CD3)2SO ppm; 14.66 (1H, s, H16), 9.10 (2H, d, H11, 17, J = 8.4), 8.88
(4H, m, H 1, 8, 20, 27), 8.48 (2H, d, H12, 15), 8.23 (2H, t, H7, 21), 8.13
(6H, m, H13, 14, 2, 26, 9, 19), 7.96 (2H, t, H 10,18), 7.86 (2H, d, H5,
23), 7.61 (4H, m, H4, 24, 6, 22), 7.36 (2H, t, H 3, 25). 13C NMR ppm;
156.72, 156.51, 151.47 (C 34, 61), 151.37 (C 31, 64), 150.21 (C 38,
57), 145.36, 137.96 (C 36, 59), 137.81 (C29, 66), 133.45& 133.29 (C
47, 50), 130.49 (C 40, 55), 127.89 (C 35, 60), 127.72 (C 30, 65), 127.04
(C 46, 51), 126.50 (C39, 56), 124.44 & 124.35 (C 28, 37, 58, 67),
118.51 (C49), 112.25 (C48).

2.3.5. Synthesis of [Ru(phen)2p-CPIP]2+
cis-[Ru(phen)2Cl2].2H2O (0.142 g, 0.25 mmol) and p-CPIP (0.080 g,
0.3 mmol) were dissolved in 50 mL ethanol: water (1:1 v/v) and heated
under reﬂux for 8 h. Yield: 0.151 g (77%). Elemental analysis (%) calculated for [Ru(C12H8N2)2(p-C20H11N5)][PF6]2·1(H2O): C 48.45, H:
2.68, N: 11.68; found C 48.24, H: 2.44, N: 11.66. MALDI-TOF (m/z):
[M-H]+ Actual mass: Actual mass: 782.1353; Calculated mass:
782.1355 1H NMR (400 MHz) in (CD3)2SO ppm; 14.63(1H, s, H16),
9.06 (2H, br s, H11, 17), 8.79 (4H, m, H3, 6, 22, 25), 8.48 (2H, d, H12,
15), 8.41(4H, s, H 4, 5, 23, 24), 8.16 (4H, d, H13, 14, 9,19), 8.08 (4H,
m, H1, 8, 20, 27), 7.80 (6H, m, H, 2, 7, 21, 26, 10, 18). 13C NMR ppm;
152.82 &152.63(C28, 39, 60, 71), 150.75& 150.55 (C40, 59), 147.18,
147.09, 145.74, 136.82(C30, 37, 62, 69), 133.36 & 133.29 (49, 52),
130.42(C42, 57), 128.03 (33, 34, 65, 66), 127.02(C48, 53), 126.33&
126.27(C41, 58, 29, 38,61, 70), 118.5 (C51), 112.27(C50).
2.3.6. Synthesis of [Ru(phen)2m-CPIP]2+
The complex was synthesised as described for [Ru(phen)2p–CPIP]2+
with m-CPIP (0.080 g, 0.3 mmol) replacing p-CPIP. Yield: 0.153 g
(78%). Elemental analysis (%) calculated for [Ru(C12H8N2)2(mC20H11N5)][PF6]2·3(H2O): C 46.90, H: 2.95, N: 11.19; found C 46.70, H:
2.60, N: 10.96. MALDI-TOF (m/z): [M-H]+ Actual mass: 782.1367;
Calculated mass: 782.1355. 1H NMR (400 MHz) in (CD3)2SO ppm; 14.3
(1H, s, H16), 9.03 (2H, d, H11, 17, J = 8.4), 8.79 (4H, d, H3, 6, 22, 25),
8.67 (1H, s, H15), 8.61 (1d, H12) 8.41 (4H, s, H 4,5, 23, 24), 8.15
(2H,d, H1, 8), 8.07 (5H, m, H14, 9, 19, 20, 27), 7.83 (7H, m, H13, 10,
18, 2, 7, 21, 26). 13C NMR ppm; 152.81 (C28, 39), 152.62(C60, 71),
150.66 & 150.39 (C40, 59), 147.17, 147.09, 145.69, 136.81 (C30, 37,
62, 69), 133.54(C50), 130.93 (C48), 130.56(C49), 130.42(C42, 57),
130.33, 129.03 (C53), 128.03 (C33, 34, 65, 66), 126.33(29, 38, 61, 70,
41, 58), 118.27 (C51), 112.37 (C52).

2.3.2. Synthesis of [Ru(bpy)2m-CPIP]2+
The complex was synthesised as described for [Ru(bpy)2p–FPIP]2+
with m-CPIP (0.080 g, 0.3 mmol) replacing p-FPIP. Yield: 0.139 g
(76%). Elemental analysis (%) Calculated for [Ru(C10H8N2)2(mC20H11N5)][PF6]2·2(H2O): C 45.29, H: 2.95, N: 11.88; found C 45.01, H:
2.65, N: 11.80. MALDI-TOF: (m/z): [M-H]+ Actual mass: 734.1388;
Calculated mass: 734.1355. 1NMR (400 MHz) in (CD3)2SO ppm; 14.7
(1H, s, H16), 9.06 (2H, d, H11, 17, J = 8.4), 8.88 (4H, m, H 1, 8, 20,
27), 8.67 (1H, s, H15), 8.62 (1H,d, H12), 8.23 (2H, d, H 7, 21, J = 8),
8.10 (5H, m, H14, 2, 26, 9, 19), 7.91 (5H, m, H13, 5, 23, 10, 18), 7.61
(4H, m, H 4, 24, 6, 22), 7.35 (2H, t, H 3, 25). 13C NMR ppm; 156.72 (Q),
156.51, 151.46 (C 34, 61), 151.36 (C 31, 64), 150.11 (C 38, 57),
145.24, 137.95 (C 36, 59), 137.80 (C 29, 66), 133.54 (C 48), 130.95 (C
46), 130.71 (C 47), 130.34 (C 40, 55), 129.65 (C 51), 127.88 (C 35, 60),
127.73 (C 30, 65), 126.46 (C 39, 56), 124.43 & 124.35 (C 28, 37, 58,
67), 118.29 (C49), 112.38 (C50).

2.3.7. Synthesis of [Ru(phen)2o-CPIP]2+
The complex was synthesised as described for [Ru(phen)2p–CPIP]2+
with o-CPIP (0.080 g, 0.3 mmol) replacing p-CPIP. Yield: 0.133 g (68%).
Elemental analysis (%) calculated for [Ru(C12H8N2)2(o-C20H11N5)]
[PF6]2·2(H2O): C 47.66, H: 2.82, N: 11.37; found C 47.61, H: 2.42, N:
11.03. MALDI-TOF (m/z): [M-H]+ Actual mass: 782.1366; Calculated
mass: 782.1355. 1H NMR (400 MHz) in (CD3)2SO ppm; 14.63(1H, s,
H16), 9.01 (2H, d, H11, 17), 8.79 (4H, d, H3, 6, 22, 25), 8.42 (4H, d,
H4, 5, 23, 24), 8.26 (1H, d, H12), 8.17 (3H, m, H13, 1, 8), 8.12 (2H, dd,
H, 20, 27), 8.05(3H, m, H14, 9, 19), 7.81 (7H, m, H 15, 2,7, 21, 26, 10,
18). 13C NMR ppm; 152.85 (C28, 39), 152.63 (C60, 71), 150.63 (C40,
59), 149.69, 147.18, 147.10, 145.77, 136.77 (C30, 37, 61, 68), 135.29
(C49), 133.65 (C50), 132.02, 130.62 (C52), 130.42 (C42, 57), 130.35,
129.41 (C48), 128.02 (C33, 34, 64, 65), 126.32 & 126.26 (C29, 38, 61,
70, 41, 58), 118.07 (C51), 110.27 (C53).

2.3.3. Synthesis of [Ru(bpy)2o-CPIP]2+
The complex was synthesised in an identical manner as described
for [Ru(bpy)2p–FPIP]2+ with o-CPIP (0.080 g, 0.3 mmol) replacing pFPIP. Yield: 0.103 g (56%). Elemental analysis (%) Calculated for [Ru
(C10H8N2)2(o-C20H11N5)][PF6]2·3(H2O): C 44.54, H: 3.08, N: 11.69;
found C 44.68, H: 3.18, N: 11.68. MALDI-TOF MS (m/z): [M-H]+ Actual
mass: 734.1389; Calculated mass: 734.1355. 1H NMR (400 MHz) in
(CD3)2SO ppm; 14.7 (1H, s, H16), 9.07 (2H, d, H11, 17, J = 8), 8.87
(4H, m, H 1, 8, 20, 27), 8.23 (3H, d, H12, 7, 21), 8.1 (5H, m, H15, 2, 26,
9, 19), 8.03 (1H, t, H13), 7.96 (2H, m, H 10,18), 7.86 (3H, m, H14, 5,
23), 7.50 (4H, m, H 4, 24, 6, 22), 7.36 (2H, t, H 3, 25). 13C NMR ppm;
156.72, 156.49, 151.51 (C 34, 61), 151.37 (C 31, 64), 150.17 (C 38,
57), 145.36, 137.95 (C 36, 59), 137.79 (C 29, 66), 135.30, 133.66 (C
48), 130.5 (C46), 129.43 (C47), 127.72 (C 39, 56), 127.0 (C 30, 65),
124.42 & 124.32 (C 28, 37, 58, 67), 118.5 (C49), 110.31 (C51).

2.4. DNA binding studies

2.3.4. Synthesis of [Ru(phen)2m-FPIP]2+
The complex was synthesised as described for [Ru(phen)2p–FPIP]2+
with m-FPIP (0.097 mg, 0.3 mmol) replacing p-FPIP. Yield: 0.129 g
(66%). Elemental analysis (%) Calculated for [Ru(C12H8N2)2(mC20H12N4)][PF6]2·3(H2O): C 46.78, H: 3.03, N: 9.92; found C 46.52, H:
3.28, N: 9.71. 1H NMR (400 MHz) in (CD3)2SO ppm; 14.61 (1H, s, H17),
10.19 (1H, s, H15), 9.08 (2H, d, H11, 18, J = 8.4), 8.84 (1H, s, H16),
8.78 (4H, d, H3, 6, 23, 26), 8.65(1H, s, H12, J = 8), 8.41 (4H, s, H4, 5,
24, 25), 8.15 (3H, m, H14, 1, 8), 8.46 (2H, d, H 21, 28), 8.03 (2H, d, H
9, 20), 7.92(1H, t, H13), 7.80 (6H, m, H 2, 7, 22, 27, 10, 19). 13C NMR
ppm; 193.06 (C15), 152.80 (C29, 40), 152.62 (C61, 72), 150.39 (C41,
60), 147.19, 147.11, 145.54, 136.93 & 136.79 (C31, 38, 63, 70),

A number of diﬀerent instrumental techniques were utilised to study
the interactions between DNA and the synthesised Ru(II) complexes.
The methodology of selective discrimination allowed the elimination of
the least favourable complexes after each technique. This allowed
emphasis to be placed on the complexes showing the most promising
results. The various techniques that were used to study the binding of
the complexes with DNA included electronic spectroscopy (UV/Vis and
ﬂuorescent), circular dichroism (CD), and thermal denaturation (TD)
[30,31].
The following study was carried out with deoxyribonucleic acid
(DNA) sodium salt from calf thymus (CT) (Sigma Aldrich) prepared in
freshly prepared Sodium Cacodylate/Na2EDTA buﬀer (pH = 7).
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results in hypochromism and bathochromism shifts, due to the intercalation mode involving a strong π-π stacking interaction between an
aromatic chromophore and the base pairs of DNA [33]. The extent of
the hypochromism in the UV/Vis band is consistent with the strength of
the intercalative interaction. Percentage hypochromism (H %) is deﬁned by Eq. (1.4) [33].

2.4.1. Buﬀer
10 mM
(0.2510 g)
Sodium
cacodylate
trihydrate
[Na
(CH3)2AsO2·3H2O] and 0.1 mM (0.0037 g) Na2EDTA solution was prepared with 90 mL of pure water in a beaker and brought to a pH of 7.0
by the drop-wise addition of 1 M HCl. The solution was transferred into
a 100 mL volumetric ﬂask and made up to the mark with deionised
water.

H% = 100% ×
2.4.2. Preparation of the DNA solution
6.4 mg of CT-DNA was placed into an ependorf tube and 1 mL of the
cacodylate/EDTA buﬀer (pH 7) was added. The ependorf was placed in
a beaker of ice water and sonicated (4/5 times for 3 s intervals). The
DNA solution was syringed out from the ependorf, and ﬁltered with a
45 μL membrane (Whatman) into a fresh ependorf tube.

2.4.5. Circular dichroism
DNA:complex samples of diﬀerent ratios; 160:1, 80:1, 40:1, 24:1,
20:1, 16:1, 12:1, 6:1 were prepared. A set concentration of 150 μM of
DNA was used. The volume is pipetted into the sample vial containing
2 mL of the buﬀer. The initial Ru complex concentration was 25 μM,
upon which varying concentrations were titrated into the DNA buﬀered
solutions and incubated overnight at 37 °C. Circular dichroism (CD) is
the diﬀerence in absorption of left (Aℓ) and right circularly polarized
light (Ar) as shown in Eq. (1.5) [35]:

2.4.4. Determining the complex/DNA binding constant (Kb)
The initial complex–DNA interaction study was carried out by UV/
Visible absorption spectroscopy. Monitoring of spectral changes in the
absorption proﬁle of the complex or the DNA molecules can allow the
calculation of an equilibrium binding constant (Kb) and the site binding
size (s) [25]. The equilibrium binding titration technique was used
where the complex solution of a ﬁxed concentration (15 μM) is transferred into a thermostated cuvette containing 2000 μL of buﬀer and the
progressive absorbance changes were monitored after each addition of
serial aliquots from a stock DNA (10 mM) solution. Additions of DNA
into the complex solution and the resultant reduction in absorbance
(hypochromic shift) and a bathochromic shift in the λmax were recorded. Aliquots of DNA were added until there was a no further reduction in the absorption intensity. Each cuvette was maintained at a
constant temperature of 25 °C by the peltier temperature programmer
(PerkinElmer PTP-1 Peltier system). Between each sample addition, the
cuvette was inverted several times for even distribution and to allow for
thermal equilibrium for approximately 10 min prior to measurement.
The absorbance (A) measured at any wavelength reﬂects both the free
and DNA-bound complex species as shown in Eq. (1.1) [32].

CD = A ℓ − Ar

(1.1)

(1.2)

b = 1 + KbC t + Kb [DNA]/ 2s

(1.3)

(1.5)

2.4.6. Thermal denaturation
The melting temperature (Tm) of the DNA solution, which is deﬁned
as the temperature where half of the total base pairs are unbound, is
usually measured to study the interaction of transition metal complexes
with nucleic acid. Generally, the melting temperature of DNA increases
when metal complexes bind to DNA by intercalation, as intercalation of
the complexes between DNA base pairs causes stabilisation of base pair
stacking and hence raises the melting temperature of double-stranded
DNA [32]. The thermal denaturation experiment was performed on the
UV/Vis spectrophotometer by recording the absorbance at 260 nm as a
function of temperature. The DNA to complex ratio for all of the samples was set at 10:1; DNA (50 μM) and complex solution (5 μM). The
temperature was increased at a thermal gradient of 0.4 °C/min and
readings were taken every 2 °C within the range of 40–90 °C. Experiments were run in triplicate and averages obtained.
The melting of DNA can be monitored very eﬃciently using UV/Vis
absorption spectroscopy. Because of their aromatic structure, each of
the four DNA bases has a characteristic absorption spectrum, the sum of
the absorption spectra of the four aromatic bases has (λmax = 260 nm)
[32]. When DNA melts and the two strands separate, the electronic
interactions between the bases are modiﬁed and the entire absorption
spectrum increases in intensity [32]. This increase in absorption due to
melting is typically between 30 and 40% [32].

where C is the ﬁxed complex concentration (Cf, free and Cb, bound) and
εf and εb represent the respective extinction coeﬃcients. The intrinsic
DNA binding constant Kb were obtained from monitoring the change in
the absorbance of the MLCT λmax according to the following Eqs. (1.2)
and (1.3) [33].
1/2
2
(εa − ε f )/(εb − ε f ) = ⎛⎜b − ⎛b 2 − 2K C t [DNA]/ s⎞ ⎞⎟/ 2KbC t
b
⎝
⎠ ⎠
⎝

(1.4)

The interaction of the complexes with calf thymus DNA (CT-DNA)
began with electronic absorption titrations which, allows determination
of the binding aﬃnity and percentage hypochromism.
The Ru(II) complexes were further explored by thermal denaturation and circular dichroism experimentation. Thermal behaviours of
DNA in the presence of complexes can give insight into DNA conformational changes when the temperature is raised and oﬀers information about the interaction strength of the complexes with DNA.
According to the literature, the intercalation of natural or synthesised
organic and metallointercalators generally result in a considerable increase in melting temperature (Tm) [34].

2.4.3. UV/Vis DNA titration
The DNA solution was checked for homogeneity by the addition of
speciﬁc amounts of calf thymu-DNA (1–10 μL) into 2 mL of the sodium
cacodylate/EDTA buﬀer. The DNA solutions were quantiﬁed spectrophotometrically using the Beer lambert law (ɛ260 = 6600 M−1 cm−1). A
working standard from the stock DNA was prepared of 5 mM, of which
set aliquots of DNA was added to the ruthenium samples. The purity of
the DNA was checked by monitoring the value of A260/A280. The ratio
was in excess of 1.80 for all samples used in the experiments so that the
contents of residual proteins should be small. [26].

A = Af + Ab = ε f Cf + εb Cb

(Afree–Abound)
Afree

where [DNA] is the concentration of DNA in nucleotides, εa is the extinction coeﬃcient (Aabs / [M]) observed for the MLCT absorption band
at a given DNA concentration, εf and εb are the extinction coeﬃcients
for the free Ru(II) complex and the extinction coeﬃcient for the Ru(II)
complex in the fully bound form, respectively. Kb is the equilibrium
binding constant in M−1, Ct is the total Ru(II) complex concentration
and s is the binding site size [32].
An inorganic complex binding to DNA through intercalation usually

2.4.7. Cell culture
The A375 (ATCC® CRL-1619), HeLa (ATCC® CCL-2), A549 (ATCC®
CCL-185), BEAS-2B (ATCC® CRL-9609) and MCF7 (ATCC® HTB22) cell
lines were all purchased from the ATTC (Manassas, VA, USA). All tested
cell lines were cultured in RPMI-1640 medium supplemented with 10%
FBS (foetal bovine serum), 45 IU/mL penicillin, 45 IU/mL streptomycin
and L-glutamine (1%) (HeLa media) at 37 °C in a humidiﬁed incubator
at 5% CO2.
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3. Results and discussion

2.4.8. In vitro cytotoxicity
A cytotoxicity assessment for the complexes and isolated ligands
were conducted with the MTT assay. All complexes were tested against
the cells over the concentration 250–0.9 μM, whereas the ligand were
tested over a broader range of 500–1.9 μM, to ensure an appropriate
dose response in the cytotoxic proﬁle as to calculate IC50 values as a
result of the exposures. In all viability experiments a 10% dimethyl
sulfoxide (DMSO) was also used as a positive kill control to validate
assay function in all exposures. For testing, stock concentrations of all
complexes and ligands were prepared using fully supplemented media,
which were diluted further with fully supplemented media by serial
dilution for deﬁnitive concentration range testing. For the MTT assay
cells were seeded in 96 well microtitre plates (Nunc, Denmark) at a
density of 1 × 105 cells/mL for 24 h exposure and 3 × 104 cells/mL for
96 h exposures respectively, in 100 μL of medium containing 10% FBS.
Three independent experiments were conducted and eight replicate
wells were employed per concentration per plate. Following 24 h of cell
attachment, plates were washed with 100 μL/well phosphate buﬀered
saline (PBS), further treated with 100 μL/well of the respective complex
under test and incubated for the required time point. After exposure,
the medium for the controls or test exposures were removed, the cells
were washed with PBS. Stock solution of MTT was prepared (5 mg/5 mL
of MTT in PBS) and 100 μL of freshly prepared MTT in media (1 mL/
10 mL of MTT stock in media (without FBS or supplements) were added
to each well. After 3 h incubation, the medium was discarded and the
cells were rinsed with PBS and 100 μL of MTT ﬁxative solution (DMSO)
were added to each well and the plates were shaken at 240 rpm for
10 min. The absorbance was then measured at 595 nm in a SpectraMax
M3 Multi-Mode Microplate Reader (Molecular Devices, USA).

3.1. Electronic absorption titration
Electronic absorption spectroscopy is a reliable method to investigate the interactions of macromolecules with DNA. In this study
UV/Vis absorption titrations were employed to investigate the propensity of a library of ruthenium polypyridyl complexes to bind to calf
thymus DNA. The binding strength, site size and mode of action were
seen to diﬀer with variation of both the co-ordinated and auxiliary ligands attached to the metal centre. The auxiliary ligands exhibit signiﬁcant absorption features in the DNA absorption region and as such it
was more prudent to monitor the absorption peak of the ruthenium
complex for evidence of interaction. The aim of this biological study is
to evaluate the potential of a series of Ru based complexes to intercalate/interact with DNA. As such it is critical to ﬁrst evaluate the eﬀect
of the isolated coordinated ligands and their aﬃnity to DNA. This will
allow the elucidation of the impact of the metal centre in relation to the
potential of DNA binding.
Fig. 2 shows the eﬀect of varying concentration of CT-DNA
(0.01–0.8 mM) on the electronic absorption spectra of 27.5 μM of the
isolated NPIP (left) and FPIP (right) and The intense broad absorption
band of these ligands occur in the UV region (380 nm) due to a strong
intra-ligand transition between π and π* energy levels of the polypyridyl ligands aromatic system. The graphs below show no spectral
shifting and no isobestic point is present. This suggests a lack of interaction between the ligand and the DNA.
3.2. Fluorescence DNA titration
Fluorescence spectroscopy another technique commonly used to
study interactions between small ligand molecules and DNA. The advantages of molecular ﬂuorescence over other techniques are its high
sensitivity, large linear concentration range and selectivity. The series
of polypyridyl ligands (FPIP, BPIP, CPIP and NPIP) proved to be intensely ﬂuorescent.
In the case of ﬂuorescence, a signiﬁcant increase in the ﬂuorescence
emission is normally observed for intercalative modes of interaction
while a decrease in the ﬂuorescence intensity is observed for groove
binding agents, electrostatic, hydrogen binding or hydrophobic interactions [32]. In Fig. 3 a slight reduction in ﬂuorescence intensity is
observed with the increased DNA concentration however this is not a
signiﬁcant observation and can be attributed to a dilution eﬀect due to
the incrementally added DNA volume. This is further evidence that the
free ligands do not strongly interact with DNA. The experimental data
from the aforementioned UV/Vis and ﬂuorescence binding titrations is
reinforced by circular dichroism measurements at diﬀerent complex:DNA ratios for the ligands. CD was performed on the ligands as one

2.4.9. Statistical analysis
In all in vitro testing at least three independent experiments with
eight replicate wells per exposure concentration were conducted in
triplicate for all experiments. Test results for each assay were expressed
as percentage of the unexposed control ± standard deviation (SD).
Control values were set at 100%. Statistical analysis was performed on
the raw data using GraphPad Prism version 7. Data were analysed by
Two-way analysis of variance (ANOVA)-Tukeys multiple comparison
tests to detect signiﬁcance in eﬀects between exposure groups and
Sidak multiple comparison tests to detect for signiﬁcance in eﬀects
within the groups. Statistically signiﬁcant diﬀerences in tests were indicated for p value < 0.05. Cytotoxicity data for the MTT assay was
ﬁtted to a sigmoidal curve and four parameter logistic model to calculate the IC50 values and they were reported as ± 95% conﬁdence
interval. All quoted IC50 values were estimated using GraphPad Prism
7.0.
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Fig. 2. The eﬀect of varying concentration of CT-DNA (0.01–0.25 mM) on the electronic absorption spectra of 25 μM of NPIP (left) and FPIP (right).
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Fig. 3. Emission (left) and Circular Dichroism (right) spectrum of FPIP in buﬀer at 25 °C in the presence of increasing amounts of CT-DNA.

ﬁnal test to conﬁrm the lack of interaction. Fig. 3 shows the CD spectrum of the isolated FPIP ligand and it is evident from the spectrum that
no new features are introduced with the addition of the DNA; again the
peak reduction can be attributed to a dilution eﬀect.

appearance of two isobestic points near ~275 and ~475 nm. This
phenomenon was observed for all of the complexes. All of the [Ru
(phen)2L]2+ and [Ru(bpy)2L]2+ when titrated with CT-DNA produced
hypochromic and bathochromic shifts. These shifts are due to the intercalation of the complex, involving a strong π-π stacking interaction
between an aromatic chromophore and the base pairs of DNA. The
extent of the hypochromism in the UV/Vis band is analogous with the
strength of the binding interaction. On average the ruthenium complexes consisting of the phenanthroline auxiliary ligands produced the
highest percentage hypochromic shift, followed by the bipyridine
complexes. It has been well documented that the phen and bpy based
complexes show a large hypochromic shift in the spectral intensity. The
values found in this study are consistent with reported values for the
percentage hypochromic shift e.g. [Ru(phen)2dppz]2+ = 18.9% and
[Ru(bpy)2pip]2+ = 21.9% [36–38]. The largest percentage hypochromic shifts were produced by the NPIP terminated complexes, with
[Ru(phen)2NPIP]2+ and [Ru(bpy)2NPIP]2+ measuring 27.4% and
25.6% respectively which directly correlates with the higher calculated
binding constants in Table 2. Considerable large hypochromic shift was
seen for all of the series of [Ru(phen)2L]2+ and [Ru(bpy)2L]2+ complexes. The CPIP, FPIP and BPIP complexes all display a reduction in
the MLCT absorption band of 16.6, 19.1 and 18.1% respectively for the
[Ru(phen)2L]2+ and 19.1, 18.2 and 17.6% respectively for the [Ru
(bpy)2L]2+. When examining the hypochromic shifts as a function of
the positional changes on the main polypyridyl ligand (para, meta and
ortho), it is worth noting that it is the ortho positioned nitrile groups
(CN) producing the least % hypochromic shift, alongside their slightly
lower binding constants (Kb); ([Ru(phen)2o–CPIP]2+ = 11.5% and [Ru
(bpy)2o–CPIP]2+ = 5.6%). While the para and meta positioned nitrile
complexes produce consistently higher hypochromic shifts of ~18%
coinciding with their higher Kb binding constants. This suggests that the
para and meta CPIP complexes are more strongly binding to DNA base
pairs than the ortho analogues. This result can be expected, on the basis

3.3. Complex DNA titration
The isolated main ligands show a negligible aﬃnity for DNA, the
systematic study is to evaluate the ruthenium complexes in the presence
of CT-DNA. The [Ru(phen)2L]2+ complexes, where L = p-FPIP, p-CPIP,
p-NPIP and p-BPIP show absorption maxima at 456, 458, 463 and
453 nm but upon addition of DNA exhibit UV/Vis absorption maxima at
460, 460, 461 and 459 nm respectively. The electronic absorption
spectra of the [Ru(bpy)2L]2+, complexes, where L = p-FPIP, p-CPIP, pNPIP and p-BPIP show similar characteristics and shift to 460, 462, 457
and 461 nm respectively when bound to DNA.
The intercalative binding with DNA results in hypochromic and
bathochromic shifts and this is evident in the absorption spectrum of
the novel [Ru(phen)2p-CPIP]2+ complex, Fig. 4. The reduction and red
shift in absorbance is typical of the intercalative mode involving a
stacking interaction between the ligand chromophore and the base
pairs of DNA, the extent of the hypochromism is usually consistent with
the strength of intercalative interaction [30]. The initial hypochromic
and slight bathochromic shifts can best be described by the lowering in
MLCT and π and π* transition energy of the metal and ligand in Ru(II)
complexes due to their ordered stacking between the DNA base pairs
after intercalation [30]. After binding to the DNA, the π orbital of the
binding ligand is free to couple with π orbital of the base pairs in the
DNA. The coupling π orbital was partially ﬁlled by electrons, thus decreasing the transition probabilities, and hence resulting in the hypochromicity. Thus, the energy level of the π–π* transition decreases, and
results in a red shift [30].
The above shifts in absorbance are accompanied with the
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Fig. 4. Absorption spectra (left) of [Ru(phen)2p-CPIP]2+ in buﬀer at 25 °C in the presence of increasing amounts of CT-DNA, (right) zoomed in MLCT region of [Ru(phen)2p-CPIP]2+;
arrow indicates the change in absorbance upon increasing DNA concentration.
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Table 2
DNA binding site size (s), binding constants (Kb) and thermal denaturation melting point
(Tm) of the Ru(II) complexes.

[Ru(phen)2pCPIP]2+
[Ru(phen)2mCPIP]2+
[Ru(phen)2oCPIP]2+
[Ru(phen)2pBPIP]2+
[Ru(phen)2pFPIP]2+
[Ru(phen)2pNPIP]2+
[Ru(bpy)2p-CPIP]2+
[Ru(bpy)2mCPIP]2+
[Ru(bpy)2o-CPIP]2+
[Ru(bpy)2p-BPIP]2+
[Ru(bpy)2p-FPIP]2+
[Ru(bpy)2pNPIP]2+
[Ru(bpy)3]2+
Actinomycin D
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Fig. 5. Melting temperature curves for CT-DNA in the absence (C) and presence of the
following complexes, [Ru(phen)2p-CPIP]2+ (P), [Ru(phen)2m-CPIP]2+(M) and [Ru
(phen)2o-CPIP]2+ (O). [DNA] = 50 μM, [Ru] = 5 μM, (10:1 ratio).

with large % hypochromic shifts of 28 and 26% respectively giving
similar experimental binding constants yielded by the [Ru
(bpy)2p–NPIP]2+ synthesised in this study of 1 × 106 M−1 [40].
Table 2 depicts the interaction of [Ru(phen)x-CPIP]2+ and CT-DNA
with a systematically varied positional group on the CPIP polypyridyl
ligand; where x is a para, meta or ortho position. When examining the
ruthenium (II) complexes, via regioisomers eﬀect, a noticeable diﬀerence on the DNA binding constants can be observed. Three novel
phenanthroline based regioisomers were chosen; [Ru(phen)2p-CPIP]2+,
[Ru(phen)2m-CPIP]2+ and [Ru(phen)2o-CPIP]2+ to study their interaction and stabilisation eﬀect that they could produce on CT-DNA. The
melting temperature (Tm) values of each of these complexes are shown
in Table 2, relative to CT-DNA.
Fig. 5 is a plot of all the regioisomers relative to CT-DNA. When
examining the data from the regioisomer viewpoint the para and meta
and ortho substituted nitrile groups all followed the same trend of; [Ru
(phen)2p-CPIP]2+ (80 °C) > [Ru(phen)2m-CPIP]2+ (79.7 °C) > [Ru
(phen)2o-CPIP]2+ (77.3 °C). Experiments were run in triplicate and
averages allowed this ﬁgure to be obtained. This trend is also evident in
the bipyridine complexes: [Ru(bpy)2p-CPIP]2+ (75.2 °C) > [Ru
(bpy)2m-CPIP]2+ (72.9 °C) > [Ru(bpy)2o-CPIP]2+ (69.9 °C) as in
Table 2.
The large change in Tm suggests the binding aﬃnities of the ruthenium complexes with DNA are very strong [41]. From Table 2, it
may be observed that varying degrees of ΔTm (°C) were achieved by the
complexes depending on their auxiliary ligand and polypyridyl ligand
end group. The largest change (Δ °C) was observed by the complexes
with the phenanthroline auxiliary ligands (15.4–6.6 °C), while the
complexes with the bipyridine auxiliary ligands resulted in a (ΔTm)
increase range of 11.9–5.3 °C. The large increase in Tm result is typical
of complexes which intercalate between the base pairs of DNA, stabilizing the duplex structure. The potential of the main polypyridyl ligands can also be observed and marked diﬀerences can be seen by end
groups and positional changes. The CPIP and FPIP terminated complexes stabilized the DNA core and raised the melting temperature by
15.4 °C and 15.2 °C for the complexes with the phenanthroline auxiliary
ligand. The NPIP and BPIP of the same series of complexes producing
smaller Tm values theses are still within the range expected of intercalative complexes. Overall the best produced Tm values came from the
complexes bound to the phenanthroline auxiliary ligands followed
closely by the bipyridine complexes producing large Tm values also. The
experimental results the complexes containing the bipyridine auxiliary
ligands, also suggests an intercalative binding mode.
The large increase in Tm result is typical of complexes which

that the para and meta substituted ligands possess a greater planar area
and an extended π system, hence higher hydrophobicity than that of the
ortho substituted ligand, which would lead to p-CPIP and m-CPIP penetrating more deeply into, and stacking more strongly to CT-DNA
[39]. A complex binding to DNA through intercalation usually results in
hypochromism and bathchromism, due to the intercalation mode involving a strong π–π stacking interaction between an aromatic chromophore and the base pairs of DNA. It seems to be generally accepted
that the extent of the hypochromism in the UV/Visible region is consistent with the strength of the intercalative interaction [33].
The intrinsic binding constant, Kb for the complexes [Ru(bpy)2pNPIP]2+ and [Ru(phen)2o-CPIP]2+ were found to be 1 × 106 M−1 and
0.4 × 106 M−1 respectively. The calculated binding constants are all
within the range of 0.2–5 × 106 M−1 up to the order of 107 M−1, which
coincides with what has been reported for classical intercalators and
metallointercalators [37,38].
The DNA binding aﬃnity of complex [Ru(phen)2NPIP]2+
(Kb = 5 × 106 M−1) is remarkably greater than that of the bipyridine
counterpart with a Kb = 1 × 106 M−1. Progression to the CPIP series
also follows the same pattern of [Ru(phen)2CPIP]2+ yielding a binding
constant of Kb = 0.9 × 106 M−1, the bipyridine analogue binding
constant being smaller at 0.7 × 106 M−1. The [Ru(phen)2FPIP]2+
complex follows this same pattern yielding a binding constant of
Kb = 1 × 106 M−1, with the bipyridine analogue binding constant
being smaller (Kb = 0.3 × 106 M−1).
As both [Ru(phen)2L]2+ and [Ru(bpy)2L]2+ analogues of the
complexes were studied by UV/Vis DNA titrations the eﬀect of the bidentate auxiliary ligands (bpy and phen) on the binding aﬃnity can be
observed. The diﬀerence in the binding constants indicates that the
phen auxiliary ligand enhances the DNA-binding aﬃnity compared
with the bpy auxiliary ligand, since two of the complexes have the same
intercalative ligands.
Shi et al. synthesised the Ru(II) complexes with their main polypyridyl ligand (L) the NPIP ligand structure synthesised in this study,
(where L is o-NPIP (1), m-NPIP (2) and p-NPIP (3)) containing NO2 at
diﬀerent positions on the phenyl ring with the bpy auxiliary ligand
[35]. Their para positioned NO2 complexes were isolated for the stereoisomers which were found to produce binding constants of Kb
0.82 × 106 M −1 for the Δ isomer and 0.73 × 106 M −1 for the Λ isomer
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interaction variation in binding modes prevent trends and correlations
being presented as the auxiliary ligand eﬀect far outweighs any eﬀect
that would be induced due to end-group of positions changes on the
intercalative ligand. Apart from the structural variation that will result
from the planarization of polypyridyl ligands with the variation of the
auxiliary ligand, size and steric issues will also play a part in restricting
DNA binding. The variation of auxiliary ligand plays a large role in the
mode of action inducing a competitive dual eﬀect being the planarization of the intercalative ligand due to delocalisation of electronic and
the macroscopic eﬀect of the size and steric eﬀect of the inclusion of the
larger auxiliary ligand. It has been shown that the size of the auxiliary
ligand can play a large role in inhibiting intercalative eﬀects and from
the CD data it is obvious the larger auxiliary ligands have a profound
eﬀect on the induced CD changes [30]. The DNA studies have shown
that the most eﬀective series of complexes for strength of binding,
modiﬁcation of the both the base stacking and increasing denaturation
temperature was the [Ru(phen)2L]2+ complexes. As such the correlations shown have been conﬁned to this series as they have shown the
largest variation in DNA interaction with systematic variation of
structural parameters.
The observed melting temperature in the presence of the [Ru
(phen)2L]2+ complexes successively increased in the order of BPIP,
NPIP, FPIP and CPIP. In particular it is CPIP and FPIP that stabilize the
DNA helix the best resulting in the largest increase of the melting point.
These two speciﬁc complexes [Ru(phen)2p–CPIP]2+ and [Ru
(phen)2p–FPIP]2+ also aﬀected the CD spectrum of DNA with the most
pronounced induced peak developing at 265 nm. When you plot the
change in the CD spectrum (275 nm reduction and 265 nm growth) as a
function of the increase in melting temperature (Tm) the graph is shown
in Fig. 6 is resultant.
Fig. 6 shows the ΔCD intensity of [Ru(phen)2p–L]2+complexes
whereby L is the para substituted polypyridyl ligands consisting of the
four main end groups (FPIP, CPIP, NPIP and BPIP) as a function of the
ΔTm generated by complexes in the presence of DNA. This graph correlates the change in the thermal denaturation temperature (Δ Tm from
DNA temperature) produced by each complex with the diﬀerence in
epilicity intensity of the induced peak (ΔCD) at 275 nm. The increased
size of the induced CD peak follows the same marked eﬀect as observed
in the thermal denaturation (Tm) results of the complexes bound to
DNA. From the thermal denaturation results (Table 2) the [Ru
(phen)2p–CPIP]2+ complex showed the largest Tm of 80 °C (ΔTm of
+15.4 °C) and it also generated the largest induced peak on the DNA
CD spectrum as shown in Fig. 6, followed closely by the FPIP terminated complex (Table 2). The evidence shows that the phen complexes
containing the most electron withdrawing group NO2 (NPIP) and least
electron withdrawing group i.e. bromine (BPIP) produced the smallest

intercalate between the base pairs of DNA, stabilizing the duplex
structure. The binding Tm results are comparable to those of structurally
similar ruthenium (II) polypyridyl complexes such as; [Ru
(phen)2(APIP)]2+ (1) and [Ru(phen)2(HAPIP)]2+(2); (whereby
(APIP) = 2-(2-Aminophenyl)imidazo
[4,5-f][1,10]phenanthroline
(polypyridyl ligand with an ortho substituted amine group) and
HAPIP = 2-(2-Hydroxyl-5-aminophenyl)imidazo [4,5-f][1,10]-Phenanthroline (meta substituted amine group and ortho substituted hydroxyl
group). Their DNA-binding behavior was analysed by electronic absorption titration and thermal denaturation studies yielding Kb values
for the complexes of 3.38 × 105 M−1 and 3.93 × 105 M−1 respectively.
The observed change of melting temperatures (ΔTm) in the presence of
complexes 1 and 2 are 68.4 °C (Δ = +7.8 °C) and 71.9 °C
(ΔTm = +11.3 °C) respectively Liu et al. also synthesised another two
promising ruthenium (II) complexes [Ru(bpy)2(DBHIP)]2+(1) and [Ru
(phen)2(DBHIP)]2+(2); (where DBHIP = (2-(3,5-dibromo-4-hydroxyphenyl)imidazo[4,5-f][1,10]phenanthroline (polypyridyl ligand with
two meta substituted Br groups and a para substituted hydroxyl group)).
Both complexes increased the melting temperatures (ΔTm) in the presence of DNA as follows; (1) 75.2 °C and (2) 76.8 °C respectively with an
initial DNA Tm of 68.9 °C [41].
Furthermore two ruthenium (II) complexes with a benzofuran group
instead of a disubstituted benzene group of the polypyridyl type ligands
synthesised in this thesis have shown comparable results. Du et al.
synthesised [Ru(bpy)2(bﬁpH)]2+ (1) and [Ru(phen)2(bﬁpH)]2+ (2)
(where bﬁpH = 2-(benzofuran-2-yl)imidazo[4,5-f] [1,10] phenanthroline) which produced intrinsic binding constants, Kb of 4.59 × 106 M−1
and 6.37 × 106 M−1 determined by the McGheeVon Hippel (MVH)
model [42]. Also these two complexes [Ru(bpy)2(bﬁpH)]2+ (1) and [Ru
(phen)2(bﬁpH)]2+ (2) presented thermal melting curves with a Tm
within a similar range to the complexes analysed in this chapter;
Tm = 78.8 °C and 79.5 °C for complexes 1 and 2 respectively, at the
exact same concentration ratio [Ru]/[DNA] 1:10. The large increases in
Tm of DNA with the two Ru(II) complexes (ΔTm is 18.4 and 19.1 °C for 1
and 2, are comparable to that observed for classical intercalators).
Other signiﬁcantly well-known complexes have had the melting points
of DNA increased by 13 and 16 °C for ethidium bromide (EB) and Δ-[Ru
(phen)2(dppz)]2+, respectively [42].
The eﬀects of the two renowned antitumour ruthenium(III) complexes; NAMI (sodium trans-(dimethylsulfoxide)(imidazole)tetrachloro
ruthenate(III)) and RAP (dichloro-1,2-propylenediamine tetraacetate
ruthenium(III)) Ru(III)) have also been reported in the literature. One of
these compounds, NAMI is endowed with potent antimetastatic properties and has been analysed to determine its thermal denaturation
proﬁle with calf thymus DNA. It was established from the experimental
data that both NAMI and RAP complexes induce a slight stabilisation of
the double helix ΔTm for NAMI is +2.5 °C and RAP is +1 °C [38].
Notably the eﬀects induced by these signiﬁcant complexes on the
melting proﬁles of calf thymus DNA are smaller than those produced in
vitro by the novel Ru complexes in this study, as expected due to their
diﬀerent mode of action. The ruthenium complexes analysed by L.
Messori et al. acknowledged that the interactions do not fully represent
the molecular basis for the biological eﬀects of ruthenium complexes;
however they do help establish that DNA constitutes a reasonable target
for these biologically active ruthenium (III) complexes, especially since
some ruthenium (III) complexes have previously been shown to accumulate preferentially in the cell nucleus [43,44].
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3.4. DNA binding studies trends and correlations
The binding constants for the ruthenium complexes presented in
Table 2 elucidated the roles of the ancillary ligand, end group and regioisomers on both the spectroscopic and biological eﬀect via DNA
interaction. Variation of the auxiliary ligands has been shown to of
huge interest when attempted to tailor the electronic properties of the
complexes, however when accessing the biological eﬀect of DNA
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Fig. 6. The Δ CD intensity of [Ru(phen)2p-L]2+ complexes plotted versus the ΔTm
(logarithmic scale) (whereby p-L = para substituted FPIP, CPIP,NPIP and BPIP).
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of their mode of action or the required time for the complex to enter the
cell and localise at the site of action the DNA containing nucleus, but
further more detailed testing would be required to verify this and to
determine the exact mechanism of action of the complexes. Interestingly the complexes were noted to be most eﬀective when tested on the
A375 cell line, a dermal cancer cell line, with the IC50 values a factor of
10 lower for all the complexes indicating that the complexes may hold
promise in the treatment of dermal cancers. When compared to the
normal cell control some complexes showed a lower IC50 value in the
tumour derived cell lines than that of the normal BEAS2B line indicating a higher degree of eﬃcacy in tumour lines than that of the
normal cells. When compared to a commercially utilised chemotherapeutic of similar structure and function, such as cisplatin, these complexes show excellent promise. Studies have shown that cisplatin requires longer incubation times in vitro to elicit the full eﬀect, with IC50
values in immortalised cancer cells decreasing from 166 μM after 24 h
exposure to 4.81 μM after 96 h exposure reported [46]. In all of the
complexes tested here, in all cells lines, the IC50 values decreased
dramatically with increased exposure time indicating that the ruthenium complexes eﬃcacy increases with exposure time. In all of the
complexes tested here, in all cells lines, the IC50 values decreased
dramatically with increased exposure time indicating that the ruthenium complexes eﬃcacy increases with exposure time. The mechanism
of action and further biological investigation of the compounds are
ongoing. The DNA intercalation studies have shown that the complexes
intercalate with DNA suggesting that their primary mechanism of action will be that of DNA damage, interestingly it was only the full
complexes that were noted to intercalate and not the free ligands. This
would suggest the presence of the ligand are not signiﬁcant contributors
to the overall toxicity but rather act as a targeting moiety to improve
uptake of the ruthenium complexes. To verify this isolated ligand exposures were employed on selected cell lines yielding IC50 values
(Table 4) although they did exhibit cytotoxicity, the IC50 values estimated for ligands were not comparable to the complexes and as such it
is postulated in the complex form they do not signiﬁcantly contribute to
the overall observed cytotoxicity levels of the complexes. The results
achieved would be of a comparable magnitude to that reported recently
by Wan et al. [6], Tang et al. [8] and Zhang et al. [4] for similar
structured complexes.

increase in the DNA core temperature (Δ = +7.8 °C and 6.6 °C) while
also generating the least eﬀective induced peak in the CD spectra at the
same DNA: complex ratios. This would suggest that although the NO2
and Br complexes are the best intercalators and also that the mode of
action for the more polar main ligands is diﬀerent in nature that for the
more electronically neutral FPIP and CPIP.
It has been illustrated that the imidazole stretching frequency as
measured by Raman spectroscopy could be used a measure of the
electronic coherence across the imidazole bridge of the main intercalative ligand [45]. This increased electron density would create the
planarised form of the ligand and also the variation in stretching frequency can be seen as an accurate measure of the rotational and steric
freedom. If the binding constant of the complexes, when unhindered by
the auxiliary ligand size, is directly related to the planarity of the intercalated ligand, then it would be expected that the Raman frequency
would be well correlated with the binding constant. Fig. 7 shows a plot
of the Raman frequency as a function of the binding constant for the
phen and bpy series.
It is evident that the parameters plotted in the graph in Fig. 7 are
well-deﬁned, the bpy as mentioned earlier show as invariance in
binding constants with the changing of the end-groups however the
phen series show a gradual increase in the binding aﬃnity as the imidazole ring stretch in strengthened.
3.5. In vitro cytotoxicity
A preliminary cellular viability screen was performed on the parasubstituted complexes to test eﬃcacy against both normal and tumour
based cell lines. The para-substituted complexes were selected following the DNA binding constants and thermal denaturation results
which suggested that the para-substituted complexes show stronger
interaction with DNA over the meta and ortho counterparts. The cell
lines employed; A375 (Skin Cancer), HeLa (Cervical Cancer), A549
(Lung Cancer), Beas2B (Lung Normal Cell) and MCF-7 (Breast Cancer),
were chosen to reﬂect many diﬀerent target organs and cell type. All
viability levels were monitored with the aid of the MTT assay.
The calculated IC50 values are presented in Table 3, as can be seen
all the tested complexes displayed promising toxicity levels with variations observed between both, tumour and normal lines and target
organ. Most of the complexes were noted to be more eﬀective after the
longer time point exposure of 96 h, as evident by the lower IC50 values
calculated, indicating that the complexes take in excess of 24 h to
achieve greater cytotoxic eﬀects. It is postulated that, based on the DNA
intercalation studies, the complexes will bind to DNA and most likely
cause fragmentation interrupting the cell cycle and ultimately result in
cell death. This increase in cytotoxicity over time may be a direct result

4. Conclusion
The binding properties of a series of novel ruthenium complexes to
DNA of the general structure; [Ru(phen)2L]2+and [Ru(bpy)2L]2+
whereby L is a planar aromatic polypyridyl ligand (CPIP, FPIP,NPIP and
BPIP) were investigated using various biophysical techniques.
Regioisomers were biologically evaluated of three series of complexes
of the structure; [Ru(phen)2x-CPIP]2+ and [Ru(bpy)2x-CPIP]2+ where
x = para, meta and ortho. As previously mentioned it is thought that the
main target for ruthenium (II) complexes is DNA and their direct
binding to DNA consequently resulting in DNA damage so three biophysical techniques were chosen to determine the potential of these
novel complexes; UV/Vis DNA titrations, circular dichroism and
thermal denaturation. The conclusions drawn from the biological experimental suggests the signiﬁcance of the auxiliary ligand; especially
1,10-phenanthroline has on the binding constants (Kb). The results
suggest that the [Ru(phen)2L]2+ complexes intercalate more eﬃciently
and are attracted to DNA even more so than [Ru(bpy)2L]2+ analogues.
In spite of their structural similarities the overall DNA action of the
complexes diﬀer signiﬁcantly from each other especially when looking
at them from end group and positional eﬀect. The aldehyde and nitrile
group end on the polypyridyl ligand exhibited more eﬀective DNA
binding via an intercalative mode when combining the binding constant
(Kb), thermal denaturation (Tm) values and pronounced induced CD
peak on the chiral DNA peak.
DNA binding constants show all types of binding, covalent and non-
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Fig. 7. The imidazole stretch frequency of [Ru(phen)2p–L]2+ complexes plotted versus
the binding constant (Kb) whereby p-L = para substituted FPIP, CPIP,NPIP and BPIP.
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Table 3
IC50 values calculated from the mean response of three independent experiments with 8 replicates per independent Statistically signiﬁcant diﬀerences in tests were indicated for p
value < 0.05. Cytotoxicity data for the MTT assay was ﬁtted to a sigmoidal curve and four parameter logistic model to calculate the IC50 values and they were reported as ± 95%
conﬁdence interval. All quoted IC50 values were estimated using GraphPad Prism 7.0.
Compound/Cell lines

A375 24 h μM

A375 96 h μM

HeLa 24 h μM

HeLa 96 h μM

A549 24 h μM

A549 96 h μM

BEAS2B 24 h μM

BEAS2B 96 h μM

MCF-7 96 h μM

[Ru(phen)2p-CPIP]2+
[Ru(phen)2 p-NPIP]2+
[Ru(phen)2 p-FPIP]2+
[Ru(phen)2 p-BPIP]2+
[Ru(bpy)2 p-CPIP]2+
[Ru(bpy)2 p-NPIP]2+
[Ru(bpy)2 p-FPIP]2+
[Ru(bpy)2 p-BPIP]2+

11.8
47.0
24.8
34.6
85.2
40.3
99.2
73.2

2.88
11.2
9.52
12.6
8.11
26.3
38.5
21.4

283
1370
265
77.2
281
322
1580
203

12.6
86.4
90.9
45.2
45.4
38.9
285
104

46.5
420
531
38.5
164
223
765
228

9.56
130
201
12.1
28.3
346
1140
139

61
486
407
111
262
105
258
142

14.3
114
67.8
44.5
32.5
21.0
55.4
39.2

17.7
38.9
163
20.9
64.4
86.5
377
283
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Table 4
IC50 values (μM) for ligands were calculated from the mean response after a 24 h exposure of three independent experiments with 8 replicates per independent. Statistically
signiﬁcant diﬀerences in tests were indicated for p value < 0.05. Cytotoxicity data for
the MTT assay was ﬁtted to a sigmoidal curve and four parameter logistic model to
calculate the IC50 values and they were reported as ± 95% conﬁdence interval. All
quoted IC50 values were estimated using GraphPad Prism 7.0.
Ligand

HeLa (μM)

BEAS2B (μM)

A549 (μM)

FPIP
CPIP
BPIP

300
270
10

40
760
10

130
290
11
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doi.org/10.1016/j.jinorgbio.2018.01.018.
References
[1] L. Zeng, O. Gupta, Y. Chen, E. Wang, L. Ji, H. Chao, Z.S. Chen, Chem. Soc. Rev. 46
(2017) 5771–5804.
[2] K.E. Erkkila, D.T. Odom, J.K. Barton, Chem. Rev. 99 (9) (1999) 2777–2796.
[3] http://theralase.com/pressrelease/theralase-anti-cancer-technology-presentedinternational-conference/.
[4] S. Zhang, Q. Wu, H. Zhang, Q. Wang, X. Wang, W. Mei, X. Wu, W. Zheng, J. Inorg.
Biochem. 176 (2017) 113–122.
[5] S. Swavey, K. Morford, M. Tsao, K. Comfort, M.K. Kilroy, J. Inorg. Biochem. 175
(2017) 101–109.
[6] D. Wan, S.H. Lai, C.C. Zeng, C. Zhang, B. Tang, Y.J. Liu, J. Inorg. Biochem. 173
(2017) 1–11.
[7] O. Mazuryk, M. Lomzik, D. Martineau, M. Beley, M. Brindell, G. Stchel, P.C. Gos,
Inorg. Chim. Acta 443 (2016) 86–90.
[8] B. Tang, B.J. Han, D. Wan, S.H. Lai, X.Z. Wang, C. Zhang, C.C. Zeng, Y.J. Liu,
Transit. Met. Chem. 42 (5) (2017) 373–386.
[9] G.B. Jiang, Y.Y. Xie, G.J. Lin, H.L. Huang, Z.H. Liang, Y.J. Liu, J. Photochem.
Photobiol. B Biol. 129 (2013) 48–56.
[10] G. Li, L. Sun, L. Ji, H. Chao, Dalton Trans. 45 (34) (2016) 13261–13276.
[11] M.R. Gill, J.A. Thomas, Chem. Soc. Rev. 41 (8) (2012) 3179–3192.
[12] L. Salassa, Eur. J. Inorg. Chem. (2011) 4931–4947.
[13] H. Chao, R.H. Li, C.W. Jiang, H. Li, L.N. Ji, X.Y. Li, J. Chem. Soc. Dalton Trans.
(2001) 1920–1926.
[14] H. Chao, H. Li, R.H. Li, J.Y. Zhou, L.N. Ji, Polyhedron 19 (2000) 1975–1983.
[15] J. Liu, W.J. Mei, L.J. Lin, K.C. Zheng, H. Chao, F.C. Yun, L.N. Ji, Inorg. Chim. Acta
357 (2004) 285–293.
[16] H. Xu, K.C. Zheng, L.J. Lin, H. Li, Y. Gao, L.N. Ji, J. Inorg. Biochem. 98 (2004)
87–97.
[17] X. He, L. Zeng, G. Yang, L. Xie, X. Sun, L. Tan, Inorg. Chim. Acta 408 (2013) 9–17.
[18] A. Bencini, V. Lippolis, Coord. Chem. Rev. 254 (2010) 2096–2180.
[19] J. Reedijk, Platin. Met. Rev. 52 (1) (2008) 2–11.
[20] T. Gianferrara, I. Bratsos, E. Alessio, Dalton Trans. (2009) 7588–7598.
[21] L.N. Ji, X.H. Zou, J.G. Liu, Coord. Chem. Rev. 216–217 (2001) 513–536.
[22] L.F. Tan, H. Chao, X.H. Zou, J.G. Liu, Polyhedron 26 (2007) 3029–3036.
[23] L.F. Tan, H. Chao, H. Li, Y.J. Liu, B. Sun, W. Wei, L.N. Ji, J. Inorg. Biochem. 99
(2005) 513–520.
[24] L.F. Tan, F. Wang, H. Chao, Y.F. Zhou, C. Weng, J. Inorg. Biochem. 101 (2007)
700–708.
[25] S. Page, Ed. Chem. 49 (2012) 1.
[26] R.H. Zheng, H.C. Guo, H.J. Jiang, K.H. Xu, B.B. Liu, W.L. Sun, Z.Q. Shen, Chin.
Chem. Lett. 21 (2010) 1270–1272.
[27] N.N. Sergeeva, M.D. Marechal, G.M. Vaz, A.M. Davies, M.O. Senge, Bioorg. Med.
Chem. Lett. 21 (2011) 4385–4388.
[28] G. Sprintschnik, H.W. Sprintschnik, P.P. Kirsch, D.G. Whitten, J. Am. Chem. Soc. 99
(15) (1977) 4941–4954.
[29] S. Shuo, J. Liu, J. Li, K.C. Zheng, C.P. Tan, L.M. Chen, L.N. Ji, Dalton Trans. (2005)
2038–2046.
[30] M. Sirajuddin, S. Ali, A. Badash, J. Photochem. Photobiol. B Biol. 124 (2013) 1–19.
[31] W. Zhong, J.S. Yu, Y. Liang, K. Fan, L. Lai, Spectro. Chimica. Acta. A 60 (2004)
2985–2992.
[32] K.R. Fox, Drug-DNA Interaction Protocols, Springer Protocols, Methods in
Molecular Biology, 2nd ed, Humana Press, 2010.
[33] L.M. Chen, J. Liu, J.C. Chen, C.P. Tan, S. Shi, K.C. Zheng, L.N. Ji, J. Inorg. Biochem.

covalent, intercalating and electrostatic binding and screened the potential of all the novel ruthenium complexes synthesised. The circular
dichroism experiment backed up the Kb values and allowed the complexes with the most potential to be focused on. Thermal denaturation
ﬁnalised and reinforced the intercalative ability of the ruthenium
complexes. Similar trends seen in the circular dichroism were observed
in the thermal denaturation study establishing that the complexes with
the phen auxiliary ligands giving the best results. From the end group
point of view of the nitrile terminated polypyridyl ligands stabilized the
DNA core the greatest, followed by the aldehyde terminated ligands,
the nitro group and lastly the bromine terminated ligand. It becomes
apparent that the selection in the end group of the polypyridyl ligand
has profound eﬀect on the DNA binding ability and by association the
complexes potential as a therapeutic candidate. It has been shown that
the planarity of the polypyridyl ligand, as measured by examination of
the vibrational spectrum, is directly relatable to the binding constant
(Kb). It is theorised that the ability of the Raman spectrum to take into
account steric and electronic changes in the intercalative polypyridyl
ligand via electron density variations allows the well-deﬁned relationship shown. This only holds for direct substitution on the polypyridyl
ligand as auxiliary ligand change introduces its own steric hindrances
and hence varied the mode of interaction.
All the combined techniques (UV/Vis, ﬂuorescence, circular dichroism and thermal denaturation) conﬁrms, that not only does chemical structure of the main polypyridyl ligand but the auxiliary ligand
can have a profound eﬀect on both the binding aﬃnity and mode.
The in vitro screening revealed that the produced complexes were
active in the micro molar concentration region and displayed good afﬁnity for tumour derived lines with a heightened eﬀect in the dermal
cancer model than all other target organs tested. In general, the eﬃcacy
of the tested complexes was noted to increase dramatically with increased exposure time indicating that these complexes require time in a
cellular environment to elicit their true potential with is postulated to
be via DNA intercalation inducing subsequent damage ultimately resulting in cell death. The preliminary cytotoxicity ﬁndings presented
here highlight the potential of these complexes and warrant further
more detailed studies to determine the exact mechanism of action in
vitro.

81

Journal of Inorganic Biochemistry 182 (2018) 71–82

L. Perdisatt et al.

[41] Y.J. Liu, Z.H. Liang, Z.Z. Li, J.H. Yao, H.L. Huang, J. Of, Organomet. Chem. 696
(2011) 2728–2735.
[42] K.J. Du, J.K. Wang, J.F. Kou, G.Y. Li, L.L. Wang, H. Chao, L.N. Ji, Eur. J. Med.
Chem. 46 (2011) 1056–1065.
[43] L. Messori, A. Casini, D. Vullo, S.G. Haroutiunian, E.B. Dalian, P. Orioli, Inorg.
Chim. Acta 303 (2000) 283–286.
[44] D. Frasca, J. Ciampa, J. Emerson, R.S. Umans, M.J. Clarke, Metal-Based Drugs 3 (4)
(1996) 197–209.
[45] L. O'Neill, L. Perdisatt, C.M. O'Connor, J. Phys. Chem. A 116 (44) (2012)
10728–10735.
[46] A. Kellett, M. O'Connor, M. McCann, O. Howe, A. Casey, P. McCarron, K. Kavanagh,
M. McNamara, S. Kennedy, D. May, P. Skell, D. O'Shea, M. Devereux, Med. Chem.
Commun. 2 (2011) 579–584.

102 (2008) 330–341.
[34] K. Nakamoto, M. Tsuboi, G.D. Strahan, Drug-DNA Interactions Structures and
Spectra, Wiley, New Jersey, 2008.
[35] B. Norden, A. Rodger, T. Daﬀorn, Linear Dichroism and Circular Dichroism, a
Textbook on Polarized Light Spectroscopy, RSC publishing, UK, 2010.
[36] Y.J. Jang, G.Y. Yeo, B. Park, S.K. Kim, Biophys. Chem. 158 (2011) 38–45.
[37] X.L. Liu, J.L. Lu, Y.D. Chen, L. Li, D.S. Zhang, Inorg. Chim. Acta 379 (2011) 1–6.
[38] R.B. Nair, E.S. Teng, S.L. Kirkland, C.J. Murphy, Inorg. Chem. 37 (1) (1998)
139–141.
[39] J.Z. Wu, B.H. Ye, L. Wang, L.N. Ji, J.Y. Zhou, R.H. Li, Z.Y. Zhou, J. Chem. Soc.
Dalton Trans. (1997) 1395–1401.
[40] S. Shi, J. Liu, J. Li, K.C. Zheng, X.M. Huang, C.P. Tan, L.M. Chen, L.N. Ji, J. Inorg.
Biochem. 100 (2006) 385–395.

82

